Original Source(s)
Related Content
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
7 Days Noninferior in Bacteremia
BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.
May 12, 2026
-
5 min